Artwork

Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Player FM - Podcast-App
Gehen Sie mit der App Player FM offline!

Zynex Inc. CEO Thomas Sandgaard Discusses Significant Company Growth and Future Innovations

6:51
 
Teilen
 

Manage episode 431472558 series 2891889
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to announce the company's financial and operational results for the second quarter ending June 30, 2024, in an interview with Proactive. The company achieved a remarkable 20% year-over-year increase in orders, marking the ninth consecutive quarter of record-breaking order numbers. Zynex reported an 11% year-over-year increase in second-quarter revenue, totaling $49.9 million, and a 20% increase in year-to-date cash flow from operations, reaching $3.2 million. Sandgaard emphasized the company's ongoing efforts to secure FDA approvals for next-generation devices and expand its product line in pain management. The pain management division saw a significant 20% improvement in orders compared to the previous year, highlighting strong market demand. Looking ahead, Zynex has provided guidance for the third quarter, with revenue expected to reach at least $50.0 million. Zynex's pain management devices are prescribed for various conditions, from post-surgical recovery to general pain management, by a diverse group of medical professionals, including surgeons, general practitioners, and chiropractors. .In terms of innovation, Zynex is developing new monitoring devices, including a pulse oximeter based on laser technology for more accurate blood measurements, which could also detect sepsis. This product, along with others in development, positions Zynex to potentially capture significant market share. The company aims to diversify its product portfolio. #proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare #q2 #finanacials #ThomasSandgaard, #MedicalDevices, #PainManagement, #HospitalMonitoring, #RevenueGrowth, #SalesForce, #Innovation, #PulseOximeter, #SepsisDetection, #FDAApproval, #Healthcare, #MedicalTechnology, #Chiropractors, #OrthopedicSurgery, #FinancialGrowth, #ProductDevelopment, #MarketExpansion, #NextWave, #MedicalSales#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

615 Episoden

Artwork
iconTeilen
 
Manage episode 431472558 series 2891889
Inhalt bereitgestellt von Proactive Investors. Alle Podcast-Inhalte, einschließlich Episoden, Grafiken und Podcast-Beschreibungen, werden direkt von Proactive Investors oder seinem Podcast-Plattformpartner hochgeladen und bereitgestellt. Wenn Sie glauben, dass jemand Ihr urheberrechtlich geschütztes Werk ohne Ihre Erlaubnis nutzt, können Sie dem hier beschriebenen Verfahren folgen https://de.player.fm/legal.
Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to announce the company's financial and operational results for the second quarter ending June 30, 2024, in an interview with Proactive. The company achieved a remarkable 20% year-over-year increase in orders, marking the ninth consecutive quarter of record-breaking order numbers. Zynex reported an 11% year-over-year increase in second-quarter revenue, totaling $49.9 million, and a 20% increase in year-to-date cash flow from operations, reaching $3.2 million. Sandgaard emphasized the company's ongoing efforts to secure FDA approvals for next-generation devices and expand its product line in pain management. The pain management division saw a significant 20% improvement in orders compared to the previous year, highlighting strong market demand. Looking ahead, Zynex has provided guidance for the third quarter, with revenue expected to reach at least $50.0 million. Zynex's pain management devices are prescribed for various conditions, from post-surgical recovery to general pain management, by a diverse group of medical professionals, including surgeons, general practitioners, and chiropractors. .In terms of innovation, Zynex is developing new monitoring devices, including a pulse oximeter based on laser technology for more accurate blood measurements, which could also detect sepsis. This product, along with others in development, positions Zynex to potentially capture significant market share. The company aims to diversify its product portfolio. #proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare #q2 #finanacials #ThomasSandgaard, #MedicalDevices, #PainManagement, #HospitalMonitoring, #RevenueGrowth, #SalesForce, #Innovation, #PulseOximeter, #SepsisDetection, #FDAApproval, #Healthcare, #MedicalTechnology, #Chiropractors, #OrthopedicSurgery, #FinancialGrowth, #ProductDevelopment, #MarketExpansion, #NextWave, #MedicalSales#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

615 Episoden

כל הפרקים

×
 
Loading …

Willkommen auf Player FM!

Player FM scannt gerade das Web nach Podcasts mit hoher Qualität, die du genießen kannst. Es ist die beste Podcast-App und funktioniert auf Android, iPhone und im Web. Melde dich an, um Abos geräteübergreifend zu synchronisieren.

 

Kurzanleitung